Citations

Clear

5 citation(s) found for "Huang, Yuhui".

The Reciprocity between Radiotherapy and Cancer Immunotherapy
Wang, Yifan , Liu, Zhi-Gang, Yuan, Hengfeng , Deng, Weiye , Li, Jing , Huang, Yu-Hui , Kim, Betty Y.S. , Story, Michael D. , Jiang, Wen , Huang, Yuhui , Huang, Yuhui , Jiang, Wen , Kim, Betty Y S

Mayo Clinic

Clinical Cancer Research | November 9, 2018 | Volume: 25 | Issue: 6 | Pages: 1709-1717

10.1158/1078-0432.ccr-18-2581 | PMID 30413527 Get It

Abstract The clinical success of immune checkpoint inhibitors in treating metastatic and refractory cancers has generated significant interest in investigating their role in treating locally advanced diseases, thus requiring them to be combined with standard treatments in the hope of producing synergistic antitumor responses. Radiotherapy, in particular, has long been hypothesized to have actions complementary to those of immune checkpoint blockade, and a growing body of evidence indicates that cancer immunotherapy may also have radiosensitizing effects, which would provide unique benefit for locoregional treatments. Recent studies have demonstrated that when immune cells are activated by immunotherapeutics, they can reprogram the tumor microenvironment in ways that may potentially increase the radiosensitivity of the tumor. In this review, we highlight the evidence that supports reciprocal interactions between cancer immunotherapy and radiotherapy, where in addition to the traditional notion that radiation serves to enhance the activation of antitumor immunity, an alternative scenario also exists in which T-cell activation by cancer immunotherapy may sensitize tumors to radiation treatment through mechanisms that include normalization of the tumor vasculature and tissue hypoxia. We describe the empirical observations from preclinical models that support such effects and discuss their implications for future research and trial design.
SphK1 inhibitor potentiates the anti‐cancer effect of EGCG on leukaemia cells
Kumazoe, Motofumi , Huang, Yuhui , Lesnick, Connie , Tsukamoto, Shuntaro , Kay, Neil E. , Shanafelt, Tait D. , Tachibana, Hirofumi

Mayo Clinic

British Journal of Haematology | May 25, 2016 | Volume: 178 | Issue: 1 | Pages: 155-158

10.1111/bjh.14119 | PMID 27220679 Get It

Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs
Huang, Yuhui , Kumazoe, Motofumi , Lesnick, Connie , Yamada, Shuhei , Ueda, Naoki, Suzuki, Takashi , Yamashita, Shuya, Fujimura, Yoshinori , Miura, Daisuke , Tsukamoto, Shuntaro , Kim, Yoon Hee , Kay, Neil E. , Shanafelt, Tait D. , Tachibana, Hirofumi

Mayo Clinic

Molecular Cancer Therapeutics | August 11, 2015 | Volume: 14 | Issue: 10 | Pages: 2303-2312

10.1158/1535-7163.mct-15-0185 | PMID 26264277 Get It

Abstract Activation of acid sphingomyelinase (ASM) leads to ceramide accumulation and induces apoptotic cell death in cancer cells. In the present study, we demonstrate that the activation of ASM by targeting cancer-overexpressed 67-kDa laminin receptors (67LR) induces lipid raft disruption and inhibits receptor tyrosine kinase (RTK) activation in multiple myeloma cells. Sphingosine kinase 1 (SphK1), a negative regulator of ceramide accumulation with antiapoptotic effects, was markedly elevated in multiple myeloma cells. The silencing of SphK1 potentiated the apoptotic effects of the green tea polyphenol epigallocatechin-3-O-gallate (EGCG), an activator of ASM through 67LR. Furthermore, the SphK1 inhibitor safingol synergistically sensitized EGCG-induced proapoptotic cell death and tumor suppression in multiple myeloma cells by promoting the prevention of RTK phosphorylation and activation of death-associated protein kinase 1 (DAPK1). We propose that targeting 67LR/ASM and SphK1 may represent a novel therapeutic strategy against multiple myeloma. Mol Cancer Ther; 14(10); 2303–12. ©2015 AACR.
Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles
Jiang, Wen , Huang, Yuhui , An, Yi , Kim, Betty Y.S. , Jiang, Wen , Kim, Betty Y S

Mayo Clinic

ACS Nano | July 27, 2015 | Volume: 9 | Issue: 9 | Pages: 8689-8696

10.1021/acsnano.5b02028 | PMID 26212564 Get It

Abstract 3666: Tumor microenvironment modulation enhances macrophage polarization and T-cell activation resulting in synergized anti-cancer effect
Huang, Yuhui , Jiang, Wen G. , Kim, Betty Y.S.

Mayo Clinic

Cancer Research | May 5, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 3666-3666

10.1158/1538-7445.am2014-3666 Get It

Abstract Solid cancer microenvironment is heterogeneous in nature, comprised of many stromal cell types that work in concert with malignant tumor cells for its maintenance and growth. Among these cell types, tumor-associated macrophages (TAMs) represent a dominant cell population with immunosuppressive and proangiogenic properties. Present in most human cancers, histologic evidence of increased TAMs is often associated with poorer prognosis. Here, we show that the immunosuppressive properties of TAMs can be overcome by modulating tumor microenvironmental parameters. By restoring tumor vascular network and tissue perfusion via anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody, significant reduction of tumor tissue hypoxia and acidosis can be accomplished. Alteration of these local environmental factors directly results in the polarization of TAMs from an immune inhibitory (M2-like) towards immune stimulatory (M1-like) phenotype. In addition, the restoration of aberrant and dysfunctional tumor vessels leads to changes in local cytokine and protein expression profiles that favor the recruitment of immune effector cells, including increased CXCL9 expression. As a result, both CD4+ helper and CD8+ cytotoxic T cell populations were significantly increased within the tumor. Based on these findings, we tested the utility of combining the optimal dose of anti-VEGFR2 antibody therapy with B7-H4 blockade in breast cancer models. Our preliminary data suggests that such treatment enhanced TAM polarization to an anti-tumor phenotype, increased tumor immune cell infiltration and decreased T-cell inhibition, resulting in synergized anti-cancer effects. Therefore, these results suggest that tumor microenvironment modulating therapy provides a new and interesting strategy to augment active immunotherapy for breast as well as other cancer types. Citation Format: Yuhui Huang, Wen Jiang, Betty Y.S. Kim. Tumor microenvironment modulation enhances macrophage polarization and T-cell activation resulting in synergized anti-cancer effect. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3666. doi:10.1158/1538-7445.AM2014-3666